Sorrento Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Sorrento Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Sorrento Therapeutics Inc Strategy Report
- Understand Sorrento Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sorrento Therapeutics Inc (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis and autoimmune diseases. The company’s immunotherapy pipeline portfolio consists of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for the treatment of cancer. Sorrento is investigating COVID19 programs which include Coviguard, Covidrops and Covishield, among others for the treatment of COVID-19. Its marketed products include ZTlido, a lidocaine topical system for the treatment of postherpetic neuralgia (PHN). The company works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. Sorrento is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
4955 Directors Place, San Diego, California, 92121
Website
sorrentotherapeutics.com
Telephone
1 858 2034100
No of Employees
949
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SRNEQ (OTC)
Revenue (2021)
$62.8M
18.8%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
-33.7%
(2021 vs 2020)
Market Cap*
$16.5M
Net Profit Margin (2021)
XYZ
-12.6%
(2021 vs 2020)
* As of and is in US$
Sorrento Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed: ZTlido - Postherpetic neuralgia (PHN), | ZTlido |
| Pipeline: | COVISTIX |
| COVID1-19: | COVITRACK |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In June, the company was awarded a US$4.6 million contract from the National Institute of Allergy and Infectious Diseases for the development of in vitro diagnostics for biodefense, antimicrobial resistant infections and emerging infectious diseases. |
| 2023 | Regulatory Approval | In February, the company secured an approval for the U.S. Bankruptcy Court for the Southern District of Texas for employee wages motion. |
| 2023 | Acquisitions/Mergers/Takeovers | In February, the company's through its subsidiary, Scilex acquired rights to Elyxyb (celecoxib) oral solution in Canada and the US. |
Competitor Comparison
| Key Parameters | Sorrento Therapeutics Inc | BioNTech SE | Exelixis Inc | Adaptimmune Therapeutics Plc | Atara Biotherapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Germany | United States of America | United Kingdom | United States of America |
| City | San Diego | Mainz | Alameda | Abingdon | Thousand Oaks |
| State/Province | California | Nordrhein-Westfalen | California | England | California |
| No. of Employees | 949 | 6,133 | 1,310 | 449 | 225 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Henry Ji, Ph.D. | Chairman; Chief Executive Officer; President | Executive Board | 2017 | 58 |
| Elizabeth Czerepak | Chief Business Officer; Chief Financial Officer; Executive Vice President | Executive Board | 2022 | - |
| Mike Royal, M.D. | Chief Medical Officer | Senior Management | - | - |
| Xiao Xu, M.D. | President | Senior Management | - | - |
| Alexis Nahama | Senior Vice President - Neurotherapeutics BU | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward